Skip to main content

Breast Cancer Research and Treatment

Ausgabe 2/2012

Inhalt (42 Artikel)

Preclinical Study

Catechol-O-methyltransferase genotype (Val158met) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors

César Fernández-de-las-Peñas, Carolina Fernández-Lao, Irene Cantarero-Villanueva, Silvia Ambite-Quesada, Inés Rivas-Martínez, Rosario del Moral-Avila, Manuel Arroyo-Morales

Preclinical study

Effect of anti-DR5 and chemotherapy on basal-like breast cancer

Patsy G. Oliver, Albert F. LoBuglio, Tong Zhou, Andres Forero, Hyunki Kim, Kurt R. Zinn, Guihua Zhai, Yufeng Li, Choo H. Lee, Donald J. Buchsbaum

Preclinical Study

Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer

Emi Tokuda, Yuko Seino, Atsushi Arakawa, Mitsue Saito, Fujio Kasumi, Shin-ichi Hayashi, Yuri Yamaguchi

Preclinical Study

Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity

Angelina I. Londoño-Joshi, Patsy G. Oliver, Yufeng Li, Choo Hyung Lee, Andres Forero-Torres, Albert F. LoBuglio, Donald J. Buchsbaum

Preclinical Study

C6-Ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth

Margaret Flowers, Gemma Fabriás, Antonio Delgado, Josefina Casas, Jose Luis Abad, Myles C. Cabot

Preclinical study

The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin

Osvaldo Pontiggia, Rocio Sampayo, Diego Raffo, Andrea Motter, Ren Xu, Mina J. Bissell, Elisa Bal de Kier Joffé, Marina Simian

Preclinical Study

Vascular proliferation is a prognostic factor in breast cancer

Jarle B. Arnes, Ingunn M. Stefansson, Oddbjørn Straume, Jan P. Baak, Per E. Lønning, William D. Foulkes, Lars A. Akslen

Preclinical study

Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors

Carmine Fedele, Gennaro Riccio, Carmela Coppola, Antonio Barbieri, Maria Gaia Monti, Claudio Arra, Carlo G. Tocchetti, Giuseppe D’Alessio, Nicola Maurea, Claudia De Lorenzo

Preclinical Study

Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice

Penelope D. Ottewell, Hannah K. Brown, Mark Jones, Thea L. Rogers, Simon S. Cross, Nicola J. Brown, Robert E. Coleman, Ingunn Holen

Preclinical Study

Quality of life among Egyptian women with breast cancer after sparing mastectomy and immediate autologous breast reconstruction: a comparative study

Adel Denewer, Omar Farouk, Sherif Kotb, Ahmed Setit, Seham Abd El-khalek, Mosab Shetiwy

Preclinical Study

Improving communication of breast cancer recurrence risk

Noel T. Brewer, Alice R. Richman, Jessica T. DeFrank, Valerie F. Reyna, Lisa A. Carey

Preclinical study

IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways

Tania Benatar, Wenyi Yang, Yutaka Amemiya, Valentina Evdokimova, Harriette Kahn, Claire Holloway, Arun Seth

Preclinical Study

EpCAM expression is an indicator of recurrence in basal-like breast cancer

Ayodeji J. Agboola, E. Claire Paish, Emad A. Rakha, Desmond G. Powe, R. Douglas Macmillan, Ian O. Ellis, Andrew R. Green

Preclinical study

Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours

Karolina Holm, Johan Staaf, Göran Jönsson, Johan Vallon-Christersson, Haukur Gunnarsson, Adalgeir Arason, Linda Magnusson, Rosa B. Barkardottir, Cecilia Hegardt, Markus Ringnér, Åke Borg

Preclinical study

Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts

P. Cottu, E. Marangoni, F. Assayag, P. de Cremoux, A. Vincent-Salomon, Ch. Guyader, L. de Plater, C. Elbaz, N. Karboul, J. J. Fontaine, S. Chateau-Joubert, P. Boudou-Rouquette, S. Alran, V. Dangles-Marie, D. Gentien, M.-F. Poupon, D. Decaudin

Preclinical Study

GRB7 is required for triple-negative breast cancer cell invasion and survival

Orsi Giricz, Verónica Calvo, Stephanie C. Pero, David N. Krag, Joseph A. Sparano, Paraic A. Kenny

Preclinical study

Life stage differences in mammary gland gene expression profile in non-human primates

Petra Stute, Sonja Sielker, Charles E. Wood, Thomas C. Register, Cynthia J. Lees, Fitriya N. Dewi, J. Koudy Williams, Janice D. Wagner, Ulrich Stefenelli, J. Mark Cline

Preclinical study

Lipidomic approach to identify patterns in phospholipid profiles and define class differences in mammary epithelial and breast cancer cells

M. Luísa Dória, Zita Cotrim, Bárbara Macedo, Cláudia Simões, Pedro Domingues, Luisa Helguero, M. Rosário Domingues

Preclinical Study

Epigenetic silencing of the tumor suppressor klotho in human breast cancer

Tami Rubinek, Michal Shulman, Shira Israeli, Shikha Bose, Ayelet Avraham, Adi Zundelevich, Ella Evron, Einav Nili Gal-Yam, Bella Kaufman, Ido Wolf

Preclinical study

Rates of upgrade to malignancy for 271 cases of flat epithelial atypia (FEA) diagnosed by breast core biopsy

Alexandre Peres, Emmanuel Barranger, Véronique Becette, Alain Boudinet, Jean-Marc Guinebretiere, Pascal Cherel

Clinical Trial

Upper limb progressive resistance training and stretching exercises following surgery for early breast cancer: a randomized controlled trial

Sharon L. Kilbreath, Kathryn M. Refshauge, Jane M. Beith, Leigh C. Ward, MiJoung Lee, Judy M. Simpson, Ross Hansen

Clinical Trial

Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score

Alan H. B. Wu, Wendy Lorizio, Simone Tchu, Kara Lynch, Roy Gerona, Wuyang Ji, Weiming Ruan, Kathryn J. Ruddy, Stephen D. Desantis, Harold J. Burstein, Elad Ziv

Clinical Trial

Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results

Shunji Takahashi, Takuji Iwase, Norio Kohno, Takashi Ishikawa, Tetsuya Taguchi, Masato Takahashi, Jun Horiguchi, Seigo Nakamura, Yasuo Hozumi, Masao Fukunaga, Shinzaburo Noguchi

Clinical Trial

Which prediction models best identify additional axillary disease after a positive sentinel node biopsy for breast cancer?

Tanya S. Berrang, Mary Lesperance, Pauline T. Truong, Caroline Walter, Allen H. Hayashi, Ivo A. Olivotto

Clinical Trial

Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence

Yi Ling Teo, Manit Saetaew, Suthan Chanthawong, Yoon Sim Yap, Eric Chun Yong Chan, Han Kiat Ho, Alexandre Chan

Clinical Trial

Invasive lobular breast cancer: subtypes and outcome

Monica Iorfida, Eugenio Maiorano, Enrico Orvieto, Patrick Maisonneuve, Luca Bottiglieri, Nicole Rotmensz, Emilia Montagna, Silvia Dellapasqua, Paolo Veronesi, Viviana Galimberti, Alberto Luini, Aron Goldhirsch, Marco Colleoni, Giuseppe Viale

Epidemiology

Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene

Michelle G. Rath, Farnoosh Fathali-Zadeh, Anne Langheinz, Sandrine Tchatchou, Theda Voigtländer, Jörg Heil, Michael Golatta, Sarah Schott, Teresa Drasseck, Anne Behnecke, Anna-Lena Burgemeister, Christina Evers, Peter Bugert, Hans Junkermann, Andreas Schneeweiss, Claus R. Bartram, Christof Sohn, Christian Sutter, Barbara Burwinkel

Epidemiology

Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening

Kelly A. Metcalfe, Nida Mian, Melissa Enmore, Aletta Poll, Marcia Llacuachaqui, Sonia Nanda, Ping Sun, Kevin S. Hughes, Steven A. Narod

Epidemiology

Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes

Byeong-Woo Park, Seho Park, Hyung Seok Park, Ja Seung Koo, Woo Ick Yang, Jun Sang Lee, Hyewon Hwang, Seung Il Kim, Kyong Sik Lee

Epidemiology

Health-related quality of life in male breast cancer patients

Christoph Kowalski, Petra Steffen, Nicole Ernstmann, Rachel Wuerstlein, Nadia Harbeck, Holger Pfaff

Epidemiology

The single-nucleotide polymorphisms +936 C/T VEGF and −710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population

Patricia Rodrigues, Jessica Furriol, Eduardo Tormo, Sandra Ballester, Ana Lluch, Pilar Eroles

Epidemiology

Increased diagnosis and detection rates of carcinoma in situ of the breast

J. A. Glover, F. J. Bannon, C. M. Hughes, M. M. Cantwell, H. Comber, A. Gavin, S. Deady, L. J. Murray

Epidemiology

Alcohol, genetics and risk of breast cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

Catherine A. McCarty, Douglas J. Reding, John Commins, Craig Williams, Meredith Yeager, James K. Burmester, Catherine Schairer, Regina G. Ziegler

Brief Report

Mesothelin, a novel immunotherapy target for triple negative breast cancer

Julia Tchou, Liang-Chuan Wang, Ben Selven, Hongtao Zhang, Jose Conejo-Garcia, Hossein Borghaei, Michael Kalos, Robert H. Vondeheide, Steven M. Albelda, Carl H. June, Paul J. Zhang

Letter to the Editor

The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians

Irene Catucci, Paolo Verderio, Sara Pizzamiglio, Loris Bernard, Valentina Dall’olio, Domenico Sardella, Fernando Ravagnani, Laura Galastri, Monica Barile, Bernard Peissel, Daniela Zaffaroni, Siranoush Manoukian, Paolo Radice, Paolo Peterlongo

Letter to the Editor

Germline mutations 657del5 and 643C>T (R215W) in NBN are not likely to be associated with increased risk of breast cancer in Czech women

Martin Mateju, Petra Kleiblova, Zdenek Kleibl, Marketa Janatova, Jana Soukupova, Ivana Ticha, Jan Novotny, Petr Pohlreich

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.